Physician profile
Beth A Sum
NPI 1780643734
$4,195.22
in general payments reported to CMS, 2019-2025
34 companies · $623 in 2025
The $623 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $298 · 2021: $459 · 2022: $996 · 2023: $634 · 2024: $563 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,736 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,735.65 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $565.20 | 2019-2025 | Wegovy |
| Pfizer INC. | $431.78 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $280.49 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $257.99 | 2023-2025 | |
| Agile Therapeutics, INC. | $240.26 | 2021-2024 | Twirla |
| Daiichi Sankyo INC. | $227.65 | 2019-2025 | Injectafer |
| Abbvie INC. | $220.30 | 2019-2024 | |
| Exeltis, USA INC. | $219.12 | 2021-2025 | Slynd |
| Astellas Pharma US INC | $196.73 | 2023-2025 | Veozah |
| Aspira Women'S Health INC | $177.04 | 2021-2022 | |
| Gynesonics, INC. | $158.58 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.08 | 2019-2024 | |
| Shield Therapeutics INC | $117.07 | 2023-2025 | Accrufer |
| Therapeuticsmd, INC. | $113.89 | 2019-2022 | |
| Biogen, INC. | $91.51 | 2025 | Zurzuvae |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $91.46 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Hologic Sales and Service, LLC | $86.39 | 2020-2025 | Aptima, Thinprep 2000 Processor |
| Mylan Pharmaceuticals INC. | $77.01 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $68.56 | 2019-2024 | Gardasil, Gardasil 9 |
| Millicent US INC | $62.26 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Boston Scientific Corporation | $60.00 | 2020 | |
| Baxter Healthcare | $56.78 | 2025 | Tisseel |
| Exact Sciences Corporation | $37.90 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $37.32 | 2022-2025 | Jada System |
| Myovant Sciences INC. | $28.33 | 2022 | |
| Medtronic, INC. | $26.55 | 2021 | |
| Lupin INC. | $24.86 | 2019-2020 | |
| Avion Pharmaceuticals | $23.96 | 2019-2021 | |
| Becton, Dickinson and Company | $23.77 | 2019 | |
| Scynexis, INC. | $23.61 | 2022 | |
| Channel Medsystems, INC. | $16.81 | 2023 | |
| Amag Pharmaceuticals, INC. | $14.78 | 2019 | |
| Dysis Medical, INC. | $12.18 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Sum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.